Trial site
Kindai University Hospital
- 23running trials
- 13closed trials
The trials here
What the 36 trials at this site are about, from their registry records.
- Conditions
- Lung cancer16 trials
- Gastric and oesophageal cancer5 trials
- Colorectal cancer4 trials
- Cervical cancer3 trials
- Lupus (SLE)3 trials
- Metastatic breast cancer3 trials
- Ovarian cancer3 trials
- Follicular lymphoma2 trials
- Head and neck cancer2 trials
- Liver and biliary tract cancer2 trials
- Migraine2 trials
- Pancreatic cancer2 trials
- and 12 more
- Phase
- Phase 323 trials
- Phase 1/26 trials
- Phase 25 trials
- Phase 11 trial
- Phase 2/31 trial
- Status
- Active, not recruiting17 trials
- Completed12 trials
- Recruiting5 trials
- Enrolling by invitation1 trial
- Terminated1 trial
- Lead sponsor
- Amgen8 trials
- EMD Serono Research & Development Institute, Inc.4 trials
- Biogen3 trials
- Daiichi Sankyo3 trials
- Seagen, a wholly owned subsidiary of Pfizer3 trials
- and 13 more
Running trials
Recruiting
Recruiting
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
Recruiting
Active, not recruiting
Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)
Recruiting
Active, not recruiting
Active, not recruiting
Active, not recruiting
Recruiting
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Active, not recruiting
Active, not recruiting
Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer
Active, not recruiting
Active, not recruiting
Active, not recruiting
Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01)
Enrolling by invitation
Active, not recruiting
A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer
Active, not recruiting
A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC)
Active, not recruiting
Active, not recruiting
Study of Sacituzumab Govitecan (SG) in Japanese Participants With Advanced Solid Tumors
Active, not recruiting
Active, not recruiting
Active, not recruiting
Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations
Active, not recruiting
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
- Lung cancer4 recruiting
- Gastric and oesophageal cancer2 recruiting
- Bladder cancer1 recruiting
- Cervical cancer1 recruiting
- Endometrial cancer1 recruiting
- Head and neck cancer1 recruiting
- Lupus (SLE)1 recruiting
- Melanoma1 recruiting
- Ovarian cancer1 recruiting
- Pancreatic cancer1 recruiting
- Prostate cancer1 recruiting
Closed trials
Completed
Completed
Terminated
Completed
Completed
Efficacy and Safety Study of Rimegepant for Migraine Prevention in Japanese Subjects (Japan Only)
Completed
Completed
Completed
Completed
Completed
Completed
A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2)
Completed
A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL
Completed
Site data: ClinicalTrials.govUpdated 18 Nov 2026